VivoSim Labs, Inc. (VIVS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
VivoSim Labs, Inc. stock (VIVS) is currently trading at $1.62. VivoSim Labs, Inc. PE ratio is 0.94. VivoSim Labs, Inc. PS ratio (Price-to-Sales) is 30.49. WallStSmart rates VIVS as Sell.
- VIVS PE ratio analysis and historical PE chart
- VIVS PS ratio (Price-to-Sales) history and trend
- VIVS intrinsic value — DCF, Graham Number, EPV models
- VIVS stock price prediction 2025 2026 2027 2028 2029 2030
- VIVS fair value vs current price
- VIVS insider transactions and insider buying
- Is VIVS undervalued or overvalued?
- VivoSim Labs, Inc. financial analysis — revenue, earnings, cash flow
- VIVS Piotroski F-Score and Altman Z-Score
- VIVS analyst price target and Smart Rating
VivoSim Labs, Inc.
📊 No data available
Try selecting a different time range
VIVS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · VivoSim Labs, Inc. (VIVS)
VIVS trades at a significant discount to its Graham intrinsic value of $11.97, offering a 84% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
VivoSim Labs, Inc. (VIVS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
VivoSim Labs, Inc. (VIVS) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
VivoSim Labs, Inc. (VIVS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 30.5x annual revenue
Very low institutional interest at 8.07%
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 8.30%
Supporting Valuation Data
VivoSim Labs, Inc. (VIVS) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.98) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (30.49) suggest expensive pricing. Growth concerns include Revenue Growth at 8.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -51.10%, Operating Margin at -10577.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -51.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VIVS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VIVS's Price-to-Sales ratio of 30.49x trades 119% above its historical average of 13.92x (82th percentile), historically expensive. The current valuation is 48% below its historical high of 58.99x set in Jun 2014, and 13759% above its historical low of 0.22x in Aug 2019. Over the past 12 months, the PS ratio has compressed from ~57.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for VivoSim Labs, Inc. (VIVS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
VivoSim Labs, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 142,000 with 8% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 803% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact VivoSim Labs, Inc..
Bottom Line
VivoSim Labs, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:26:07 AM
About VivoSim Labs, Inc.(VIVS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. The company is headquartered in San Diego, California.